The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants.
about
Antiplatelet and anticoagulant agents for preventing recurrence of peripheral vascular thrombosis in patients with Antiphospholipid syndromeClinical pharmacokinetic and pharmacodynamic profile of rivaroxabanDirect anticoagulant drugs to overcome limitations of vitamin K antagonists. A critical appraisal of data in atrial fibrillation patients.Thrombin induced connective tissue growth factor expression in rat vascular smooth muscle cells via the PAR-1/JNK/AP-1 pathway.Determination of rivaroxaban in patient's plasma samples by anti-Xa chromogenic test associated to High Performance Liquid Chromatography tandem Mass Spectrometry (HPLC-MS/MS).Prevention and Treatment of Lower Limb Deep Vein Thrombosis after Radiofrequency Catheter Ablation: Results of a Prospective active controlled Study.Advances in the diagnosis and treatment of acute pulmonary embolism.Stroke prevention in atrial fibrillation: impact of novel oral anticoagulants.Rivaroxaban in the treatment of venous thromboembolism and the prevention of recurrences: a practical approach.Rivaroxaban for the treatment and prevention of thromboembolic disease.Rivaroxaban: An Affordable and Effective Alternative in Cancer-Related Thrombosis?Rivaroxaban Rebound Acute Coronary Event: A Post Marketing Experience.Antiplatelet and Anticoagulant Therapies for Prevention of Ischemic Stroke.Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolism.Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring.Advances in oral anticoagulation treatment: the safety and efficacy of rivaroxaban in the prevention and treatment of thromboembolism.Evaluation of the safety and tolerability of rivaroxaban in dogs with presumed primary immune-mediated hemolytic anemia.Accelerated rejection, thrombosis, and graft failure with angiotensin II type 1 receptor antibodies.Rivaroxaban-Induced Hypersensitivity Syndrome.In vitro dissolution method fitted to in vivo absorption profile of rivaroxaban immediate-release tablets applying in silico data.Retracted: Spontaneous rectus sheath haematoma associated with rivaroxaban treatment.Evaluation of an oral direct factor Xa inhibitor anticoagulant in healthy adult horses.Direct Thrombin InhibitorsSuccessful treatment of a massive pulmonary embolism using rivaroxaban in a patient with antithrombin III deficiency
P2860
Q24185813-0EEDDBB8-0527-4DA7-954D-00056EC202D6Q26864411-3066FFA3-A5D9-4522-AFEB-A91B56AE5696Q30595943-55EAA358-957E-4225-BAF7-848F388560F9Q33566993-6A9F54FD-4A87-4C88-B46D-E6B9B78C2597Q36272889-C3A916B8-487A-403D-BC9A-B8AC540C0B45Q37027535-33A44566-C39D-4C07-878D-99B7B87ED467Q38012449-AF3CF8A5-0DC3-4FF9-8FBE-DFEECB5ADAE4Q38041072-BDE93177-47D8-41D2-B557-652D4F668AEAQ38287849-BAF94305-46B0-440E-8000-7F667B54980DQ38522824-4B5A6FA3-C417-46CF-BD08-CA62A65B22DCQ38674583-C047BCAC-B47C-4DCE-9CF9-261E278EC87CQ38869999-04A39FA1-644F-4EE8-90E1-55D25D81360DQ38909618-44DCED9D-6A79-4E28-BBB0-1C4CDCA58024Q39382147-4DBDB404-6B71-42A7-8128-D72DFC6641C5Q42188952-D3B9AF0E-0FC4-45E6-ACEA-360F7E7C2799Q42750499-28D36F06-EF0C-4A15-8631-AB2F956EF52CQ46175382-57809A65-F3E7-407C-9775-ED63D63BDE72Q46456694-5082EF9E-6A88-49BA-AFE7-928DA03B9812Q47119592-E4AC6113-9ACF-4EF8-AF0A-384456DD95BAQ47387879-9CAA064C-DD27-40E6-8B09-EB509609F9AFQ48811796-3038D286-CE51-49AC-A4D7-FCE4AB0228A7Q51778811-C61AA969-8394-4888-AAE1-77E811EC997BQ56003308-5CD4F231-99F2-4D00-BA03-4065F3E4FFF5Q57152764-15171E78-0869-463C-9DCE-E00225D1498F
P2860
The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The mechanism of action of riv ...... red with other anticoagulants.
@ast
The mechanism of action of riv ...... red with other anticoagulants.
@en
The mechanism of action of riv ...... red with other anticoagulants.
@nl
type
label
The mechanism of action of riv ...... red with other anticoagulants.
@ast
The mechanism of action of riv ...... red with other anticoagulants.
@en
The mechanism of action of riv ...... red with other anticoagulants.
@nl
prefLabel
The mechanism of action of riv ...... red with other anticoagulants.
@ast
The mechanism of action of riv ...... red with other anticoagulants.
@en
The mechanism of action of riv ...... red with other anticoagulants.
@nl
P1433
P1476
The mechanism of action of riv ...... red with other anticoagulants.
@en
P2093
Meyer Michel Samama
P304
P356
10.1016/J.THROMRES.2010.09.008
P577
2010-10-02T00:00:00Z